Thaddeus Beck

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Nasser H. Hanna, Paul A. Bunn, Corey J. Langer et al. · Journal of Clinical Oncology · 2006 · 673 citations · Full text

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Mark A. Socinski, Edward B. Garon et al. · Journal of Clinical Oncology · 2013 · 372 citations · Full text

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Nadia Harbeck, Manfred Schmitt, Christoph Meisner et al. · European Journal of Cancer · 2013 · 163 citations

Ten-year Analysis, Breast Oncology, Medicine +9

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

Wolfgang Janni, Emilio Alba, Thomas Bachelot et al. · Breast Cancer Research and Treatment · 2018 · 49 citations

First-line Ribociclib, Pain Reduction, Breast Oncology +10

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

Jordi Rodón, Giuseppe Curigliano, Jean‐Pierre Delord et al. · Oncotarget · 2018 · 45 citations · Full text